XerisDD - A Community of Due Diligence
The place to share knowledge & better understand Xeris BioPharma
Gvoke Sales Surge and Close Gap on Baqsimi in Diabetes Treatment Market
An article written by ChatGPT In the world of diabetes treatment, patients have a range of options for emergency hypoglycemic events. Two of the leading products on the market are Gvoke and Baqsimi, both of which provide a rapid-response method of treating low blood sugar. However, recent data suggests that Gvoke sales have been gaining…
What Lies Ahead For Xeris Biopharma In 2022
Jan. 1 PDUFA for Recorlev, Merck collaboration, Levothyroxine Phase 1, EIH Phase 2, and growing sales for Gvoke and Keveyis; Xeris has great potential for 2022.
Upcoming Catalysts (Xeris)
Since many people ask about upcoming catalysts, I’ve decided to put together a few things that are on the horizon. A lot of the information can be found in the ER transcripts, but I know there are a lot of lazy investors who will never read an ER transcript so I’ll do my best to…
Xeris Biopharma’s Resilience Shines Despite Tariff Turbulence
Tariffs on April 2: Big Talk, Limited Bite for Pharma Investors braced for the worst when President Trump announced “reciprocal tariffs” on April 2, 2025 – an aggressive move that some early reports hinted could mean a blanket 25% duty on all imports. In fact, Trump had publicly floated imposing 25% (or higher) tariffs on…
42nd Annual J.P. Morgan Healthcare Conference Transcript
Host: Hope you’re have hope you had a great day for at the J. P. Morgan Healthcare Conference. I’m Bhavna Balakrishnan, an associate here in the Healthcare Investment Banking Team. Thank you so much for joining the presentation of Xeris Biopharma. With us today, we have Paul Edick, who is the Chairman and Chief Executive…
Xeris Pharma: A Rising Star in the Pharmaceutical Landscape (XERS)
In a recent enlightening interview at the H. C. Wainwright’s 25th Annual Global Investment Conference, Xeris Pharma’s promising trajectory was laid bare for all to see. With CEO Paul Edick and CFO Steve Pieper at the helm, the company’s future has never looked brighter. Here’s why every investor should be bullish about Xeris Pharma. 1….
Insights from ChatGPT: Xeris Biopharma Q1 2023 Earnings Call
What does ChatGPT think about Xeris’ Q1 2023 earnings call. The following is the conversation we had: Summarizing Q1 2023 Earnings Call Transcript I’m going to post an earnings call in a few different sections. Do not summarize until all sections are posted and I will let you know they are all posted by the…
Ask A Question
Get Help From Shareholders
Ask and learn more from the XerisDD community about Financials, Products, Leadership, General, and Competition. Or select "Ask Allison" for the category, and we will ask Allison Wey, Xeris Pharma's SVP of Investor Relations & Corporate Communications.
Answer Questions
Answer Questions
